BIOMAT Database Logo BIOMAT Database Logo

Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice. 2017

Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

The influenza virus is a serious threat to public health worldwide. A novel avian influenza A (H7N9) virus with a mortality rate of approximately 30% has been identified as an unusually dangerous virus for humans by the World Health Organization. Pathogenic H7N9 continue to represent a public health concern, and several candidate vaccines are currently in development. We generated candidate H7N9 vaccine strains using reverse genetics, consisting of hemagglutinin and neuraminidase genes derived from a human H7N9 virus and the remaining genes from the PR8 (A/PuertoRico/8/34 (H1N1)) virus. This H7N9 vaccine exhibited superior efficacy when combined with MF59 compared to other adjuvants. Immunized BALB/c mice were followed to determine the duration of the protective immune response. Antibody levels decreased to between one-half and one-eighth of the peak values four months after the final dose of the vaccine. Previously vaccinated mice received an A/Zhejiang/DTID-ZJU01/2013 H7N9 challenge six months post-vaccination, and all remained protected. We also verified that MF59 enhanced the HI, MN, and IgG antibody titers to influenza antigens. The humoral immune response and Th2 cytokine production following influenza challenge was potently induced in the animals that received the split vaccine. Therefore, the split H7N9 influenza vaccine with the MF59 adjuvant could effectively induce antibody production and protect mice from H7N9 virus challenge even after six months.

UI MeSH Term Description Entries

Related Publications

Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
August 2015, Viruses,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
October 2014, JAMA,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice.
January 2009, Intervirology,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
A Canine-Directed Chimeric Multi-Epitope Vaccine Induced Protective Immune Responses in BALB/c Mice Infected with Leishmania infantum.
June 2020, Vaccines,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
March 2016, Vaccine,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice.
November 1997, Vaccine,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.
January 2019, Frontiers in microbiology,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine.
March 2010, Cellular & molecular immunology,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
Intradermal delivery of a fractional dose of influenza H7N9 split vaccine elicits protective immunity in mice and rats.
March 2018, Human vaccines & immunotherapeutics,
Huilin Ou, and Wei Yao, and Dongshan Yu, and Tianhao Weng, and Frederick X C Wang, and Xiaoxin Wu, and Haibo Wu, and Linfang Cheng, and Xiangyun Lu, and Nanping Wu, and Honglin Chen, and Lanjuan Li, and Hangping Yao
Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
December 2017, Microbes and infection,
Copied contents to your clipboard!